Healthcare / BiotechnologyCanadian Sec
$0.16
-0.01 (-5.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-846391.00 · quality 36.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-88.5%
↓Gross Margin
91.2%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+97.9%
FCF CAGR
—
FCF margin
-178.2%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $605498.0 · net income $-2.2M · FCF $-1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $605498.00 | $605498.00 | $1.0M | $532003.00 | $78070.00 |
| Net Income | $-2.2M | $-2.2M | $-823596.00 | $-779813.00 | $-985583.00 |
| EBITDA | $-2.0M | $-2.0M | $-573357.00 | $-710185.00 | $-973448.00 |
| EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Gross Margin | 91.2% | 91.2% | 85.7% | 85.4% | 97.1% |
| Operating Margin | -353.2% | -353.2% | -62.2% | -143.4% | -1262.4% |
| Net Margin | -359.2% | -359.2% | -79.6% | -146.6% | -1262.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.18 | — |
| Current Ratio | 1.42 | 1.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.1M | $-1.1M | $-547779.00 | $-846391.00 | $-1.6M |
| Returns | |||||
| ROE | -88.5% | -88.5% | -41.6% | -56.4% | -51.7% |
| Valuation | |||||
| P/B | 6.48 | 6.48 | 3.35 | 14.05 | 2.09 |
| Growth & Yield | |||||
| Revenue Growth | -41.5% | -41.5% | 94.6% | 581.4% | — |
| EPS Growth | -100.0% | -100.0% | 0.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+60.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.02
Residual
+60.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.